Avid Bioservices Inc (CDMO)

[biopharm]

2015 Gastrointestinal Cancers Symposium

January 15-17, 2015

gicasym.org/general-poster-session-b-and-trials-progress-poster-session-b-cancers-pancreas-small-bowel-and

Edcpf, nice post and the more I begin to realize that the liver is a predictable place where other cancers spread to easily, this conference will be one of interest.

-----------------------------------------------

The Gastrointestinal Cancers Symposium is a high-profile, specialized oncology event designed for the exchange of the latest research and science in cancers of the pancreas, small bowel, and hepatobiliary tract; colon and rectum; and esophagus and stomach.

http://gicasym.org/about-meeting-0

-----------------------------------------------

Liver Metastases

Liver metastases are tumors that have spread to the liver from other areas of the the body. Cancer cells often have aggressive tendencies and will invade other areas of the body. They usually do so by floating in the blood stream and then replicating themselves in a new place. The liver, in particular, provides a fertile soil for metastatic spread because of its rich blood supply and the presence of humoral factors (other bodily fluids) that promote cell growth. In terms of blood flow per minute, the blood supply of the liver is second only to the lung.

The risk of cancer spreading to the liver depends on the site of the original cancer.

For example, cancers of the GI tract often spread to the liver because their blood drains directly through the liver. Melanoma usually spreads through the body's blood vessels to the liver. Liver metastases are sometimes present when the original (primary) cancer is diagnosed, or it may occur months or years after the primary tumor is removed.

After the lymph nodes, the liver is the most common site of metastatic spread. Most liver metastases originate from the colon, rectum, pancreas, stomach, esophagus, breast, lung, melanoma and some less common sites.

http://www.surgery.ucsf.edu/conditions--procedures/liver-metastases-%28secondary-liver-cancer%29.aspx

I wonder if this is another reason why a liver deal is tough to complete and announce, because a paradigm shifting PS Targeting will possibly lead to treating Hep C and many other cancers (before metastatis) and where the cancer strikes first, and before it actually reaches and becomes liver cancer.. possibly?

All parts to the puzzle, and this just may make the case where some Big Entity is hopefully ready to realize and see how much of a paradigm shift PS Targeting truly is. Who knows... maybe we are seeing the very tip of the iceberg of the buyout of all buyouts ever before in Big Pharma. We need some updated MOA knowledge from Tustin : )

Most liver cancer is secondary or metastatic, meaning it started elsewhere in the body. Primary liver cancer, which starts in the liver, accounts for about 2% of cancers in the U.S., but up to half of all cancers in some undeveloped countries. This is mainly due to the prevalence of hepatitis, caused by contagious viruses, that predisposes a person to liver cancer. In the U.S., primary liver cancer strikes twice as many men as women, at an average age of 67.

http://www.webmd.com/cancer/understanding-liver-cancer-basic-information

Happy Thanksgiving to all : )